chart comment please, page-2

Dear Mr Turtle,

Hope all is going well for you.

If you could be so kind, please don't judge this company's prospects by it's SP chart.

Look at the advances they have made in their;
point-of-care TB testing unit,
and,
the severity of TB in the world,
the issue of TB in our 'world-village',
The degree to which their technology outstrips current procedure,
the lack of competing technology at this level,
the types of people funding their advances,
the enormous 'dollar' size of the TB testing market,

the Wheatrite test,
the Bayer connection,
the food/farming issues of the present/future,

their prostate cancer test,
the severity and widespread nature of prostate cancer as a major disease/killer of males,
it's vast improvement on present psa testing,

the speed at which medical tests can be 'stamped with approval' and brought to market in comparison to medical drugs,

their Eukarion topical compounds,
their Eukarion licence,
the implications of use of this product in medical practice, makeup, sunscreen. (do women still wear makeup these days? If so, I'm sure they don't spend much money on it), :)
it's many other dermatological and anti-radiation uses,

PXL's connection with Mr S. Porges,
his ability to 'fine tune' a company,
his connection with Minerva Healthcare,

Biotechs in general have been 'unloved' for long enough,
the love of the sector is increasing,

PXL listed at $1.20 in 2004,
has obviously be 'unloved' for a long time,
things are very different now.

I have been accumulating for well over a year now, so as a holder, my points should be taken as biased.

Cheers and have a good one,
Watko.